Abstract P2-09-24: Combination treatment with bromodomain and extra-terminal motif inhibitors in triple-negative breast cancer
Schafer, JM, Lehmann, BD, Redman, LN, Liu, P, Stubbs, M, Ruggeri, B, Scherle, P, Pietenpol, JA
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Abstract P6-05-03: Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer
Lehmann, BD, Bauer, JA, Schafer, JM, Tang, L, Pendleton, CS, Sanders, ME, Pietenpol, JA
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Get full text
Journal Article
Abstract PD01-07: Transcriptome Analysis of Triple Negative Breast Cancers Identifies Six Distinct Biological Subgroups and Reveals Therapeutic Strategies
Lehmann, BD, Bauer, JA, Chen, X, Sanders, ME, Shyr, Y, Pietenpol, JA
Published in Cancer research (Chicago, Ill.) (15.12.2010)
Published in Cancer research (Chicago, Ill.) (15.12.2010)
Get full text
Journal Article
Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)
Mayer, IA, Jovanovic, B, Abramson, VG, Mayer, EL, Sanders, ME, Bardia, A, Dillon, PM, Kuba, MG, Carpenter, JT, Chang, JC, Lehmann, BD, Meszoely, IM, Grau, A, Shyr, Y, Arteaga, CL, Chen, X(S), Pietenpol, JA
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article